FOLLOWING COMPLETE OR PARTIAL RESPONSE TO PLATINUM BASED CHEMOTHERAPY

Clinical trials for FOLLOWING COMPLETE OR PARTIAL RESPONSE TO PLATINUM BASED CHEMOTHERAPY explained in plain language.

Never miss a new study

Get alerted when new FOLLOWING COMPLETE OR PARTIAL RESPONSE TO PLATINUM BASED CHEMOTHERAPY trials appear

Sign up with your email to follow new studies for FOLLOWING COMPLETE OR PARTIAL RESPONSE TO PLATINUM BASED CHEMOTHERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Can a daily pill keep BRCA-Linked ovarian cancer at bay?

Disease control Ongoing

This Phase 3 trial is investigating whether the drug olaparib can help women with a specific type of ovarian cancer stay in remission longer. The study includes women whose cancer has returned but responded well to platinum-based chemotherapy, and who carry a BRCA gene mutation. …

Matched conditions: FOLLOWING COMPLETE OR PARTIAL RESPONSE TO PLATINUM BASED CHEMOTHERAPY

Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Jul 31, 2026 00:00 UTC

FOLLOWING COMPLETE OR PARTIAL RESPONSE TO PLATINUM BASED CHEMOTHERAPY

Get alerted when new FOLLOWING COMPLETE OR PARTIAL RESPONSE TO PLATINUM BASED CHEMOTHERAPY trials appear

Can a daily pill keep BRCA-Linked ovarian cancer at bay?